Abstract
The use of cytokines in head and neck cancer is increasingly under investigation. Clinical trials have tested the interferons, interleukin-2 and other cytokines as single agents and in various combinations. The addition of interferon to the cisplatin and 5-fluorouracil (5-FU) regimens (with and without leucovorin) has been explored. A randomized international trial comparing cisplatin and 5-FU with cisplatin, 5-FU and interferon-α 2b is in progress.
Article PDF
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
References
Vokes, E.E., Weichselbaum, R.R., Lippman, S. and Hong, W.K. (1993) Head and Neck Cancer.N. Engl. J. Med. 328, 184–94.
Mickel, R.A., Kessler, D.J., Taylor, J.M.G.et al. (1988) Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients.Cancer Res. 48, 5017–22.
Schantz, S.P., Shilltoe, E.J., Brown, B.et al. (1986) Natural killer cell activity and head and neck cancer: A clinical assessment.J. Natl. Cancer Inst. 77, 869–75.
Vlock, D.R. (1991) Immunobiologic aspects of head and neck cancer.Hematol. Oncol. Clin. North. Am. 5, 797–820.
Gasmi, J., Bachouchi, M., Cvitkovic, E., Boussen, H., Azli, N., Rahal, M., Domenge, C., Wibault, P., Eschwege, F., Schwaab, G.,et al. Nasopharyngeal carcinoma: A medical oncology viewpoint. The Gustave Roussy experience. Ann. Oncol. 1990 July1, 245–53.
Brachman, D.G., Graves, D., Vokes, E., Beckett, M., Haraf, D., Montag, A., Dunphy, E., Mick, R., Yandell, D. and Weichselbaum, R.R. (1992) The status of p53 gene deletions and human papilloma virus infection in human head and neck cancer.Cancer Res. 52, 4832–6.
Isaacs, A. and Lindenmann, J. (1957) Virus interference. I. The interferon.Proc. R. Soc. Lond. (Biol.) 147, 258–67.
Stewart, W.E. II, Blalock, J.E., Burke, D.C.et al. (1980) Interferon nomenclature.J. Immunol. 125, 2353.
Kurzrock, R., Gutterman, J.U. and Talpaz, M. (1991) Interferons alpha, beta and gamma: Basic principles and preclinical studies. In V.T. DeVita, S. Hillman and S.A. Rosenberg (eds)Biologic therapy of cancer, pp. 247–74. Philadelphia: JB Lippincott.
Foon, K.A. (1989) Biological response modifiers: The new immunotherapy.Cancer Res. 49, 1621–39.
Reiter, Z. (1993) Interferon-A major regulator of natural killer cell-mediated cytotoxicity.J. Interferon Res. 13, 247–57.
Quesada, J.R., Talpaz, M., Rios, A.,et al. (1986) Clinical toxicity of interferons in cancer patients: A review.J. Clin. Oncol. 4, 234–43.
Sacchi, M., Klapan, I., Johnson, J.T.et al. (1991) Antiproliferative effects of cytokines on squamous cell carcinoma.Arch. Otolaryngol. Head Neck Surg. 117, 321–6.
Park, R.I. and Richtsmeier, W.J. (1989) Hyperthermia effects on the growth of a laryngeal squamous cell carcinoma cell line treated with recombinant human interferons alpha and gamma.Otolaryngol. Head Neck Surg. 101, 542–8.
Ikic, D., Padovan, I., Brodarec, I.et al. (1981) Application of human leucocyte interferon in patients with tumours of the head and neck.Lancet 1, 1025–7.
Padovan, I., Brodarec, I., Ikic, D.et al. (1991) Effect of interferon in the therapy of skin and head and neck tumors.J. Cancer Res. Clin. Oncol. 100, 295–310.
Medenica, R. and Slack, N. (1985) Clinical results of leukocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule.Cancer Drug Deliv. 2, 53–76.
Connors, J.M., Andiman, W.A., Howarth, C.B.et al. (1985) Treatment of nasopharyngeal carcinoma with human leukocyte interferon.J. Clin. Oncol. 3, 813–7.
Vlock, D.R., Johnson, J., Myers, E.et al. (1991) Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck.Head Neck 13, 15–21.
Richtsmeier, W.J. (1988) Interferon gamma induced oncolysis.Arch. Otolaryngol. Head Neck Surg. 114, 432–7.
Richtsmeier, W.J., Koch, W.M., McGuire, W.P.et al. (1990) Phase I–II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma.Arch. Otolaryngol. Head Neck Surg. 116, 1271–7.
Weidmann, E., Sacchi, M. and Plaisance, S. (1992) Receptors for Interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ.Cancer Res. 52, 5963–70.
Takeda, T. (1986) Experimental approach to immunotherapy in head and neck malignant tumor-antitumor efficacy by lymphokine-activated human peripheral blood lymphocytes.Nippon Jibiinkoka Gakkai Kaiho 89, 744–53.
Heo, D.S., Whiteside, T.L., Johnson, J.T.et al. (1987) Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.Cancer Res. 47, 6353–62.
Whiteside, T.L., Heo, D.S., Takagi, S.et al. (1988) Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2.Cancer Immunol. Immunother. 26, 1–10.
Heo, D.S., Snyderman, C., Gollin, S.M.et al. (1989) Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines.Cancer Res. 49, 5167–75.
Sacchi, M., Snyderman, C.H., Heo, D.S.et al. (1990) Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.Cancer Res. 50, 3113–8.
Sacchi, M., Vitolo, D., Sedlmayr, P.et al. (1991) Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2.Int. J. Cancer 47, 784–91.
Rabinowich, H., Vitolo, D., Altarac, S.et al. (1992) Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.J. Immunol. 149, 340–9.
Forni, G., Cavallo, G.P., Giovarelli, M.et al. (1988) Tumor immunotherapy by local injection of interleukin 2 and non-reactive lymphocytes.Prog. Exp. Tumor Res. 32, 187–212.
Musiani, P., De Campora, E., Valitutti, S.et al. (1989) Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma.J. Biol. Resp. Mod. 8, 571–8.
Cortesina, G., De Stefani, A., Giovarelli, M.et al. (1988) Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically.Cancer 62, 2482–5.
Cortesina, G., De Stefani, A., Galeazzi, E.et al. (1991) Interleukin-2 injected around tumor-draining lymph nodes in head and neck cancer.Head Neck 13, 125–131.
Mattijssen, V., De Mulder, P.H., Schornagel, J.H.et al. (1991) Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma.J. Immunother. 10, 63–8.
Rivoltini, L., Gambacorti-Passerini, C., Squadrelli-Saraceno, M.et al. (1990)In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.Cancer Res. 50, 5551–7.
Selvaggi, K.J., Vlock, D.R., Johnson, J.T.et al. (1990) Phase Ib trial of peritumoral and intranodal injections of IL-2 in patients with advanced squamous cell carcinoma of the head and neck (abstract).Proc. Am. Soc. Clin. Oncol. 9, 690.
Melioli, G., Margarino, G., Scala, M.et al. (1992) Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and squamous cell carcinoma.Laryngoscope 102, 572–8.
Squadrelli-Saraceno, M., Rivoltini, L., Cantu, G.et al. (1990) Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2.Tumori 76, 566–71.
Ikawa, T., Ishikawa, T., Eura, M.et al. (1988) Study of head and neck cancer treatment by administration of autologous cytotoxic lymphocyte induced by stimulation with tumor cell-induction of killer cells by stimulation with allogeneic tumor cell.Nippon Jibiinkoka Gakkai Kaiho 91, 2079–81.
Ikawa, T., Eura, M., Fukiage, T.et al. (1989) Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer.Gan To Kagaku Ryoho 16, 1438–47.
Ishikawa, T., Ikawa, T., Eura, M.et al. (1989) Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumour cells and recombinant interleukin-2.Acta Otolaryngol. (Stockh) 107, 3346–51.
Gore, M.E., Riches, P., MacLennan, K.et al. (1992) Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck.Br. J. Cancer 66, 405–7.
Gore, M.E., Riches, P., MacLennan, K.A.et al. (1992) Intra-arterial interleukin-2 (IL-2) in squamous cell carcinoma (SCC) of the head and neck (abstract).Proc. Am. Soc. Clin. Oncol. 11, 251.
Bartsch, H.H., Pfizenmaier, K., Schroeder, M.et al. (1989) Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies.Eur. J. Cancer Clin. Oncol. 25, 287–91.
Zenner, H.-P. and Zimmermann, U. (1988) Cytotoxic effects of recombinant human biological response modifiers on head and neck carcinoma cells.ORL 50, 150–5.
Wanebo, H., Blackinton, D., Weigel, T.et al. (1991) Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.Am. J. Surg. 162, 384–7.
Schantz, S.P., Clayman, G.L., Dimery, I.et al. (1991) Combination interleukin-2 and interferon-alpha in head and neck cancer.Cancer Bull. 43, 133–8.
Schantz, S.P., Dimery, I., Lippman, S.M.et al. (1992) A phase II study of interleukin-2 and interferon-alpha in head and neck cancer.Invest. New Drugs 10, 217–23.
Schantz, S.P., Clayman, G., Racz, T.et al. (1990) Thein vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer.Arch. Otolaryngol. Head Neck Surg. 116, 1302–8.
Urba, S.G., Forastiere, A.A., Wolf, G.T. and Amrein, P.C. (1993) Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma.Cancer 71, 2326–31.
Margolin, K.A., Doroshow, J.H., Akman, S.A.et al. (1992) Phase I trial of interleukin-2 plus gamma-interferon.J. Immunother. 11, 50–55.
Hsu, M.-M., Ko, J.-Y., Chang, Y.-L. (1991) Elevated levels of soluble interleukin 2 receptor and tumor necrosis factor in nasopharyngeal carcinoma.Arch. Otolaryngol. Head Neck Surg. 117, 1257–9.
Wadler, S. and Schwartz, E.L. (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review.Cancer Res. 50, 3473–86.
Lester, E.P., Schmidt, W.K., Beckford, N.et al. (1990) Human head and neck squamous carcinoma cell lines as in vitro models for combination chemotherapy: Studies with cisplatin, 5-fluorouracil (5-FU) and interferon.Proc. Head Neck Oncol. Res. Conf. 3, 2.3.
Valone, F.H., Gandara, D.R., Deisseroth, A.B.et al. (1991) Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas.J. Immunother. 10, 207–13.
Vokes, E.E. and Weichselbaum, R.R. (1993) Combined modality therapy for head and neck cancer.Principles and Practice of Oncology Update 6, 1–2.
Vokes, E.E., Mick, R., Lester, E.P., Panje, W.R. and Weichselbaum, R.R. (1991) Cisplatin and fluorouracil does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution.J. Clin. Oncol. 9, 1376–84.
Laramore, G.E., Scott, C.B., Al-Sarraf, M.et al. (1992) Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on intergroup study 0034.Int. J. Radiation Oncol. Biol. Phys. 23, 705–13.
Wolf, G.T., Hong, W.K., Gross Fisher, S.et al. (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.New Eng. J. Med. 24, 1685–90.
Vokes, E.E., Choi, K.E., Schilsky, R.L., Moran, W.J., Guarnieri, C.M., Weichselbaum, R.R. and Panje, W.R. (1988) Cisplatin, fluorouracil and high-dose leucovorin for recurrent or metastatic head and neck cancer.J. Clin. Oncol. 6, 618–26.
Vokes, E.E., Weichselbaum, R.R., Mick, R., McEvilly, J.-M., Haraf, D.J. and Panje, W.R. (1992) Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.J. Natl. Cancer Inst. 84, 877–82.
Vokes, E.E., Ratain, M.J., Mick, R., McEvilly, J.M., Haraf, D., Kozloff, M., Hamasaki, V., Weichselbaum, R.R., Panje, W.R., Wenig, B. and Berezin, F. (1993) Cisplatin, Fluorouracil and Leucovorin Augmented by Interferon Alfa-2b in Head and Neck Cancer: A Clinical and Pharmacologic Analysis.J. Clin. Oncol. 11, 360–68.
Vokes, E.E., Dolan, M.E., Ratain, M.J., Ramirez, J., McEvilly, J.M., Luckett, P., Haraf, D.J., Weichselbaum, R.R., Kies, M. and Kozloff, M. (1993) Cisplatin, fluorouracil, 1-leucovorin and interferon alfa-2b for advanced head and neck cancer: A pharmacologic analysis.Proc. Am. Assoc. Cancer Res. 34, 205.
Benjamin, A., Azli, N., Domenge, C., Armand, J.P., Vokes, E.E. and Cvitkovic, E. (1992) CDDP-5FU modulation by alpha IFN 2B in metastatic and/or recurrent head and neck squamous cell carcinoma.Ann. Oncol. 3 (Suppl 5), 153.
Author information
Authors and Affiliations
About this article
Cite this article
Hamasaki, V.K., Vokes, E.E. Interferons and other cytokines in head and neck cancer. Med Oncol 12, 23–33 (1995). https://doi.org/10.1007/BF01571405
Issue Date:
DOI: https://doi.org/10.1007/BF01571405